SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Wellgistics Health, Inc.
Date: Aug. 8, 2025 · CIK: 0002030763 · Accession: 0000000000-25-008372

Financial Reporting Regulatory Compliance Business Model Clarity

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288932

Date
August 8, 2025
Author
Division of
Form
UPLOAD
Company
Wellgistics Health, Inc.

Letter

Re: Wellgistics Health, Inc. Registration Statement on Form S-1 Filed July 24, 2025 File No. 333-288932 Dear Brian Norton:

August 8, 2025

Brian Norton Chief Executive Officer Wellgistics Health, Inc. 3000 Bayport Drive, Suite 950 Tampa, FL 33607

We have conducted a limited review of your registration statement and have the following comment(s).

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1 Use of Proceeds, page 11

1. We note the disclosure surrounding your planned XRP Treasury Strategy and its execution in "the near future." If you intend on using the proceeds of this offering to purchase XRP to further your XRP Treasury Strategy, please disclose as much in this section. Refer to Instruction 5 to Item 504 of Regulation S-K. 2. We note the disclosure surrounding your planned acquisition of Peek Healthcare Technologies, Inc. If you intend on using the proceeds of this offering to finance the acquisition of Peek Healthcare Technologies, Inc., please disclose as much in this section. Refer to Instruction 6 to Item 504 of Regulation S-K. August 8, 2025 Page 2

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Nicholas Nalbantian at 202-551-7470 or Dietrich King at 202-551- 8071 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Trade &
Services
cc: Kate Bechen

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 8, 2025

Brian Norton
Chief Executive Officer
Wellgistics Health, Inc.
3000 Bayport Drive, Suite 950
Tampa, FL 33607

 Re: Wellgistics Health, Inc.
 Registration Statement on Form S-1
 Filed July 24, 2025
 File No. 333-288932
Dear Brian Norton:

 We have conducted a limited review of your registration statement and
have the
following comment(s).

 Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Use of Proceeds, page 11

1. We note the disclosure surrounding your planned XRP Treasury Strategy
and its
 execution in "the near future." If you intend on using the proceeds of
this offering to
 purchase XRP to further your XRP Treasury Strategy, please disclose as
much in this
 section. Refer to Instruction 5 to Item 504 of Regulation S-K.
2. We note the disclosure surrounding your planned acquisition of Peek
Healthcare
 Technologies, Inc. If you intend on using the proceeds of this offering
to finance the
 acquisition of Peek Healthcare Technologies, Inc., please disclose as
much in this
 section. Refer to Instruction 6 to Item 504 of Regulation S-K.
 August 8, 2025
Page 2

 We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

 Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

 Please contact Nicholas Nalbantian at 202-551-7470 or Dietrich King at
202-551-
8071 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Trade &
Services
cc: Kate Bechen
</TEXT>
</DOCUMENT>